Clinical trial
A Prospective Observational Sub-Study of the Global Hypophosphatasia Registry to Describe the Potential Risk of Immune-Mediated Loss of Pharmacological Effect of Asfotase Alfa in Participants With Hypophosphatasia
NCT05234567 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Observational Sub-Study of the Global Hypophosphatasia Registry to Describe the Potential Risk of Immune-Mediated Loss of Pharmacological Effect of Asfotase Alfa in Participants With Hypophosphatasia
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- August 25, 2022
- Completion date
- July 18, 2028
- Enrollment
- 30 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.